Kah-Whye Peng, PhD
Mayo Clinic Cancer Center (Rochester, NY)
Strategies to optimize measles virotherapy.
Live attenuated Edmonston strain measles virus (MV) has promising anti-tumor activity against a variety of human cancers and three phase I clinical trials evaluating the safety of intraperitoneal, intratumoral or intravenous delivery of MV are in progress at Mayo Clinic Rochester.
However, most patients are immunized against measles virus and have anti-viral antibodies that can inactivate the virus. This limits our ability to use measles virus in metastatic diseases that require intravenous infusion of the virus. Since measles virus naturally spreads in white cells during natural infection, we propose to use cells as vehicles to carry the virus to the tumor sites. In this way, the virus is protected from undesirable elements in the circulation and can still effectively infect tumor cells and kill them.
In this grant, we will identify the optimal protocol to load various types of cell carriers with viruses and test them in animal models. In the end, we hope to have a feasible and effective clinical protocol based on our findings to treat relapsed multiple myeloma.
Academic ProfileRead profile
Kah Whye Peng, PhD
Professor of Oncology
Mayo Clinic Cancer Center
200 First Street SW
Rochester, MN 55905